Last week’s Supreme Court decision to invalidate patents on human genes was a loss for Myriad Genetics and a win for patients and independent researchers. But the ruling is also a boon the wider biotech industry.
Last week’s Supreme Court decision to invalidate patents on human genes was a loss for Myriad Genetics and a win for patients and independent researchers. But the ruling is also a boon the wider biotech industry.
Supreme Court says no patenting (natural) genes; brain-computer interfaces mimic motor learning in brain; regenerating finger tips; gene therapy goes deeper; NIH needs more diversity; cross-border collaboration
US universities need to reach across their own borders to retain global scientific preeminence.
The NIH remains a Caucasian-dominated workforce. Why haven’t the agency’s efforts to diversify been successful?
Scientific publishers come up with a scheme to disseminate publicly funded research in response to a directive from President Obama’s top science advisor.
Democratic Senator Frank Lautenberg of New Jersey, who fought hard against the alcohol and tobacco industries, has passed away.
Was the Human Genome Project the key to a gold mine?
Take a closer look at some of the statistics generated by The Scientist's Best Place to Work Industry 2013 survey.
Publishers need to be proactive about detecting and deterring copied text.
Highways and byways are among the man-made environmental alterations driving the evolution of animals on contemporary timescales, with implications for ecology.